ASH 2023 | Outcomes of SCT in T-ALL and T-LBL
T-lineage acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) are often considered the same disease entity, but they have distinct characteristics. Although stem cell transplantation (SCT) is rare in these diseases, high-risk patients are eligible for allogeneic SCT (alloSCT), and occasionally T-LBL patients receive autologous SCT (autoSCT). Yuho Najima, MD, PhD, Komagome Hospital, Tokyo, Japan, presents a retrospective comparison that reveals similar overall survival (OS) and disease-free survival (DFS) outcomes of SCT for T-ALL and T-LBL patients. This suggests autoSCT should be considered in both T-ALL and T-LBL if patients are not eligible for alloSCT, but further prospective studies are needed to confirm this before consideration for clinical practice. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
